Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EQ001 · 2 trials · 5 indications
Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Overall Response Rate (ORR) is defined as the number of subjects with a partial response (PR), very good partial response (VGPR), or complete response (CR) who are alive at Day 29. Subjects must not have received new systemic therapy for aGVHD before the Day 29 Visit.
| Arm | Type | Description |
|---|---|---|
| EQ001 Dose Escalation (Part A) | EXPERIMENTAL | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses. |
| EQ001 (Part B) | EXPERIMENTAL | EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses. |
| EQ001 Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses. |
| EQ001 | EXPERIMENTAL | EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses. |
| EQ001 Placebo | PLACEBO_COMPARATOR | Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses. |
| Name | Type | Description |
|---|---|---|
| EQ001 | BIOLOGICAL | Itolizumab \[Bmab 600\]) |
| EQ001 Placebo | BIOLOGICAL | EQ001 Placebo |
Inclusion Criteria: 1. Male or female subject at least 18 years of age for Part A, and at least 12 years of age for Part B. 2. Recipients of allogeneic hematopoietic stem cell transplantation (alloHSCT) using myeloablative or non myeloablative conditioning regimens. 3. Have a clinical diagnosis of ...
EQ001 is an investigational monoclonal antibody being developed for acute graft-versus-host disease (aGVHD) and asthma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
EQ001 targets CD6, a protein involved in T-cell activation and proliferation. By binding to CD6, EQ001 aims to modulate the immune response, which is relevant in conditions like aGVHD and asthma.
EQ001 is being developed by Equillium, Inc., a biopharmaceutical company. Equillium is publicly traded under the ticker symbol EQ.
EQ001 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in acute graft-versus-host disease and one in asthma, but the drug remains investigational and is not yet approved.
EQ001 has completed two Phase 1 trials. NCT03763318 evaluated EQ001 in subjects with acute graft-versus-host disease, and NCT04007198 studied itolizumab (EQ001) in uncontrolled asthma. Both trials are completed.
Yes, EQ001 is also known as itolizumab. In clinical trials, it has been referred to by both names, with NCT04007198 specifically studying itolizumab (EQ001) in asthma.